Coreg CR, Blood Vessel Stiffness and Blood Vessel Function
Status:
Unknown status
Trial end date:
2009-04-01
Target enrollment:
Participant gender:
Summary
We are comparing the blood pressure-lowering effects of two marketed medications, Coreg CR
and Toprol XL. Although both drugs reduce blood pressure by blocking the action of
noradrenaline on beta-receptors in the blood vessels, Coreg CR also blocks alpha-receptors,
which may provide added blood pressure-lowering. In addition, Coreg CR may have anti-oxidant
actions. Cells which line blood vessels (termed "endothelial cells") make nitric oxide (NO),
which relaxes the muscle cells encircling the blood vessels, causing a reduction in blood
pressure. When body cells use oxygen, they normally produce "free radicals", which can
destroy NO,leading to high blood pressure, heart damage and worsenimg of diabetes.
Antioxidants remove free radicals and prevent or repair this damage. In this study we will
measure endothelial cell function, blood vessel wall stiffness, NO in exhaled breath, and
blood levels of substances which reflect NO production and destruction to determine if a pure
beta-blocker (Toprol XL) differs from an alpha/beta blocker (Coreg CR) in these effects. We
will also examine the mechanism by which such differences might occur.
Phase:
Phase 4
Details
Lead Sponsor:
State University of New York - Downstate Medical Center